Marshall Wace
IKT icon

Marshall Wace’s Inhibikase Therapeutics IKT Stock Holding History

Marshall Wace’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-155,270
Closed -$340K – 2914
2025
Q1 		$340K Buy
+155,270
New +$390K ﹤0.01% 2218

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Marshall Wace's IKT Position: Q2 2025 in Review

Marshall Wace sold out of Inhibikase Therapeutics (IKT) in Q2 2025, closing a stake of 155,270 shares — an estimated $340K sold.

Marshall Wace first reported a position in IKT in Q1 2025 and held it in 1 quarter. The position peaked at $340K in Q1 2025. 48 funds tracked by Wall St. Rank hold IKT as of Q2 2025.

  • Marshall Wace reported no remaining Inhibikase Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Marshall Wace sold 155,270 Inhibikase Therapeutics shares in Q2 2025, an estimated $340K.
  • Marshall Wace first reported a position in Inhibikase Therapeutics in Q1 2025 and held it in 1 quarter.
  • Marshall Wace's Inhibikase Therapeutics position peaked at $340K in Q1 2025.
  • 48 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2025.

Based on Marshall Wace's 13F filing for Q2 2025, filed 13 Aug 2025.